Table 2.
Clinicopathological characteristics of PDAC patients (n = 44) and CP patients (n = 7) in the immunohistochemistry cohort.
| Clinical pathological characteristics | Total (n = 51) | PDAC (n = 44) | PDAC no NAT (n = 27) | PDAC NAT (n = 17) | CP (n = 7) |
|---|---|---|---|---|---|
| Age (years), mean (SD) | 62.7 (11.1) | 64.9 (9.8) | 66.7 (9.5) | 62.1 (9.8) | 49 (9.4) |
| Gender, n (%) | |||||
| Male | 26 (51.0) | 20 (45.5) | 13 (48.1) | 7 (41.2) | 6 (85.7) |
| Female | 25 (49.0) | 24 (54.5) | 14 (51.9) | 10 (58.8) | 1 (14.3) |
| Surgery type, n (%) | |||||
| Pancreaticoduodenectomy | 36 (70.6) | 33 (75.0) | 23 (85.2) | 13 (76.5) | 3 (42.9) |
| Pancreatic corpus/tail resection | 12 (23.5) | 8 (18.2) | 2 (7.4) | 3 (17.6) | 4 (57.1) |
| Total pancreatectomy | 3 (5.9) | 3 (6.8) | 2 (7.4) | 1 (5.9) | 0 (0) |
| Tumor differentiation, n (%) | |||||
| Good | – | 5 (11.4) | 3 (11.1) | 1 (5.9) | – |
| Moderate | – | 11 (25.0) | 10 (37.0) | 1 (5.9) | – |
| Poor | – | 14 (31.8) | 11 (40.7) | 2 (11.8) | – |
| Missing | – | 14 (31.8) | 3 (11.1) | 13 (76.5) | – |
| Primary tumor, n (%) | |||||
| pT0 | – | 2 (4.5) | 1 (3.7) | 1 (5.9) | – |
| pT1 | – | 13 (29.5) | 6 (22.2) | 7 (41.2) | – |
| pT2 | – | 23 (52.3) | 15 (55.6) | 8 (47.1) | – |
| pT3 | – | 6 (13.6)) | 5 (18.5) | 1 (5.9) | – |
| Regional lymph nodes, n (%) | |||||
| pN0 | – | 11 (25.0) | 4 (14.8) | 7 (41.2) | – |
| pN1 | – | 19 (43.2) | 11 (40.7) | 8 (47.1) | – |
| pN2 | – | 14 (31.8) | 12 (44.4) | 2 (11.8) | – |
| NAT, n (%) | |||||
| No | 34 (66.7) | 27 (61.4) | 27 (100.0) | 0 | 7 (100.0) |
| Yes, chemoradiotherapy | 12 (23.5) | 12 (27.3) | 0 (0) | 12 (70.6) | 0 (0) |
| Yes, chemotherapy | 5 (9.8) | 5 (11.4) | 0 (0) | 5 (29.4) | 0 (0) |
| Tumor size (mm), mean (SD) | – | 26.7 (11.5) | 30.0 (11.9) | 21.6 (8.8) | – |
PDAC patients are categorized into two groups: NAT patients and no NAT patients.
PDAC pancreatic ductal adenocarcinoma, CP chronic pancreatitis, NAT neoadjuvant therapy, SD standard deviation.